Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Courtney D DiNardo, Aaron D. Schimmer, Karen W.L. Yee, Andreas Hochhaus, Alwin Kraemer, Richard D. Carvajal, Filip Janku, Philippe Bedard, Cecilia Carpio, Antje Wick, Gary K. Schwartz, Patrick Schöffski, Patrick Wen, Martin J. van den Bent et. al. | ||||||||||||
Title | A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/128/22/1073?sso-checked=true | ||||||||||||
Abstract Text | Blood 2016 128 (22):1073 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132X | acute myeloid leukemia | sensitive | IDH305 | Phase I | Actionable | In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073). | detail... |